. Fat-Lab, Inc., manufactures and markets a product known as “Fat Blocker.” The purpose is to change a person’s digestion of certain materials as an aid in controlling weight. The U.S. Food and Drug Administration (FDA) classified “Fat Blocker” as a drug and ordered that it be removed from the market until the FDA approved its use. The FDA claimed that it had the right to classify new products as drugs and prevent their distribution until their safety is determined. Fat-Lab disputed the FDA’s decision and wants to bring suit to halt the FDA’s actions. Do the federal courts have jurisdiction to hear this case? Explain the applicable law and your reasoning fully.